XML Template (2009) [7.9.2009–9:27am] [1–14]
{TANDF_FPP}CMO/CMO_A_370737(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
CI).
mg
b.i.d.
1.7)
49.6) 10.2) 0.18)
mg
mg
C0
C0 C0 C0
0.9) (95%
49.2 39.3
50.4)
C0
50
0.9 1.0 31.2 27.3 0.37 0.20 35.2 90.0 5.6 4.6
1000
153
C6 C6 2.0,
153
C6 C6
61.6,
131
C6 C6
16.6,
130
C6 C6
0.24,
143
C6 C6 C6 C6 2.2,
change
MF
8.7 6.9
(
C0
(
C0
(
C0
(
C0
(33.5,
143
þ 1.8
195.1 135.4
37.8 22.9 0.50 0.26 44.0 86.1
6.6 4.8
(
C0
1.6
Sitagliptin
C0 55.6 13.4 0.21
41.9
C0
mean
b.i.d.
C0 C0 C0
LS
as
expressed
mg
b.i.d.
1.3)
36.3)
8.8)
0.16)
mg mg C0
C0
C0
C0
0.0)
are
46.9 43.1
43.5)
C0
50
1.0 1.1 0.31 0.23 38.6 63.9 5.6 4.6 data
resistance.
500
147
C6 C6 1.6,
C6 C6
35.2 22.2
48.6,
115
C6 C6 15.7,
114
C6 C6
0.22,
133
C6 C6 C6 C6 1.3,
MF 8.8 7.3
(
C0
146
(
C0 (
C0
(
C0
(25.9,
133
þ
1.4
197.2 149.5
35.1 22.9 0.49 0.28 42.0 76.3
6.3 5.6
(
C0
insulin
0.7
baseline
Sitagliptin
C0 42.5
12.3
0.19
34.7
C0
for
b.i.d.
C0
C0
C0 from
change
assessment
of
b.i.d.
population). 1.2)
33.2)
9.7)
0.13)
mg C0
C0
C0
C0
0.9)
C0
deviation;
model
APT 0.8 1.0
43.3 40.5
0.21 0.19 35.1 46.7
26.5)
4.4 3.3
1000 134
C6 C6 1.5,
C6 C6
32.9 23.0
46.0,
100
C6 C6 17.1,
100
C6 C6
0.20,
126
C6 C6 C6 C6 2.3,
8.5 7.3
(
C0
134
(
C0 (
C0
(
C0
(8.5,
126
1.3
187.6 148.9
36.7 22.4 0.45 0.29 44.3 61.9
6.2 4.6
(
C0
standard
1.6
C6
homeostasis
C0 39.6
13.4
0.16
17.5
C0
(continuation
Metformin
C0
C0
C0
mean
as
HOMA-IR,
phase
b.i.d.
expressed function;
0.8)
22.2)
6.5)
0.10)
C0
C0
C0
0.1)
continuation
mg
C0 C0
are
0.9 0.9
41.3 40.9
0.30 0.21 38.4 39.5
19.7)
4.8 4.7
C12
-cell
the
500
117
C6 C6 1.2,
C6 C6
32.4 21.6
35.9, 75
C6 C6 15.0, 75 C6 C6
0.19,
102
C6 C6
0.3,
102
C6 C6 1.6,
data
for
in
8.7 7.7
(
C0
117
(
C0 (
C0
(
C0
(
C0
188.1 159.8
33.5 23.8 0.43 0.31 47.5 56.8
6.3 5.4
(
C0 54
and
1.0 0.9
A
C0 29.0
10.7
0.14
9.7
C0
week
Metformin
C0
C0
C0
and assessment
of
phase
both
baseline
model
in
q.d.
0.6)
8.7)
0.04)
mg C0
C0 1.1)
C0
1.1)
1.0 1.2
39.3 44.2
0.18 0.31 33.1 54.5
28.9)
4.2 6.0
analysis;
therapy
100
106
C6 C6 1.0,
105
C6
24.5 27.0
C6
23.2,
61 C6 C6
8.4,
61 C6 C6 0.14, 88 C6 C6 C6
0.5,
the
homeostasis
8.7 7.8
(
C0
(
C0
(
C0
(
C0
(7.3,
88 C6
0.41 0.36 40.8 58.4
5.5 6.2
(
C0
in
C12
,
active 0.8
183.0 171.2
26.4 27.1
3.7
16.0 C0
18.1 0.3
0.09
Sitagliptin
C0
C0
C0
included
HOMA-
receiving data
glucose;
groups
for
n
evaluable
plasma
n
with
fasting
(
pmol/L),
endpoints
ratio,
baseline n baseline baseline baseline baseline baseline
patients
FPG,
n
of
n
Efficacy
(%),
from from proinsulin from from from
54 54 54 54
C12
,
n
from
54 54
3. 1c
(mg/dL), number
metformin;
¼
Parameter HbA Baseline Week Change FPG Baseline Week Change Fasting Baseline Week Change Proinsulin/insulin Baseline Week Change HOMA- Baseline Week Change HOMA-IR, Baseline Week Change n MF,
Table
!
2009 Informa UK Ltd
www.cmrojournal.com 54-week efficacy and safety of sitagliptin/metformin Williams-Herman et al.
7
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34